PMID- 25661387
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20220318
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 69
DP  - 2015 Feb
TI  - Soluplus((R)) micelles as a potential drug delivery system for reversal of 
      resistant tumor.
PG  - 388-95
LID - S0753-3322(14)00223-6 [pii]
LID - 10.1016/j.biopha.2014.12.028 [doi]
AB  - Inhibiting or circumventing drug resistance by using drug delivery systems (DDSs) 
      such as micelles has attracted significant attention recently. In this present 
      study, a polyvinyl caprolactam-polyvinyl acetate-polyethylene (Soluplus((R))) 
      micelle was developed as the delivery system for doxorubicin (DOX) and evaluated 
      both in vitro and in vivo. In vitro, Soluplus((R)) micelles could significantly 
      enhance the cellular accumulation of DOX in MCF-7/DOX cells, meanwhile, 
      P-glycoprotein (P-gp)-mediated drug efflux was inhibited which was also verified 
      in the membrane fluidity study. And MCF-7/DOX cells were found to be more 
      susceptible to the cytotoxic effects of DOX-M. In vivo, both the P-gp inhibitors 
      verapamil and Soluplus((R)) could improve the cytotoxicity of DOX.HCl in MCF-7/DOX 
      tumor-bearing mice, which were further certified by the effect of Soluplus((R)) on 
      P-gp inhibition. Furthermore, the excellent antitumor efficacy of DOX-M by 
      intravenous injection was also observed, which indicated that the P-gp inhibition 
      effect of Soluplus((R)) could enhance the susceptibility of resistant tumor to DOX 
      in vivo. In conclusion, our study suggested that Soluplus((R)) micelles might be an 
      applicable drug delivery system for enhancing the antitumor efficacy of P-gp 
      substrates.
CI  - Crown Copyright (c) 2014. Published by Elsevier Masson SAS. All rights reserved.
FAU - Jin, Xiang
AU  - Jin X
AD  - College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 
      310032, PR China. Electronic address: jinxiangzjut@hotmail.com.
FAU - Zhou, Bo
AU  - Zhou B
AD  - Jiangsu Center of Safety Evaluation for Drugs, School of Pharmaceutical Sciences, 
      Nanjing University of Technology, Nanjing 210009, PR China.
FAU - Xue, Lezhen
AU  - Xue L
AD  - Jiangsu Center of Safety Evaluation for Drugs, School of Pharmaceutical Sciences, 
      Nanjing University of Technology, Nanjing 210009, PR China.
FAU - San, Weiguang
AU  - San W
AD  - College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 
      310032, PR China.
LA  - eng
PT  - Journal Article
DEP - 20141224
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Micelles)
RN  - 0 (Polyvinyls)
RN  - 0 (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & 
      inhibitors/metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Doxorubicin/pharmacology
MH  - *Drug Delivery Systems
MH  - *Drug Resistance, Neoplasm/drug effects
MH  - Endocytosis/drug effects
MH  - Female
MH  - Hep G2 Cells
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Kinetics
MH  - MCF-7 Cells
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - *Micelles
MH  - Polyethylene Glycols/*chemistry
MH  - Polyvinyls/*chemistry
OTO - NOTNLM
OT  - Antitumor efficacy
OT  - Doxorubicin
OT  - P-glycoprotein
OT  - Soluplus((R)) micelle
EDAT- 2015/02/11 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/02/10 06:00
PHST- 2014/11/25 00:00 [received]
PHST- 2014/12/11 00:00 [accepted]
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S0753-3322(14)00223-6 [pii]
AID - 10.1016/j.biopha.2014.12.028 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2015 Feb;69:388-95. doi: 10.1016/j.biopha.2014.12.028. Epub 
      2014 Dec 24.